IFAPP

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine

National Member Associations

IFAPP consists of the leading professional associations in pharmaceutical medicine and drug development.

Education

Worldwide Development and Professional Certification

Communication

Excellent Global Communication Since 1975

Collaborations

IFAPP collaborates and coordinates with key players in the fields of pharmaceutical medicine and medicines development

Certification Working Group

CCWG works collaboratively in the development and delivery of relevant and recognised education and training in PM/MDS for the benefit of IFAPP’s professional membership.

The Board of Officers

The current members of the IFAPP Board of Officers are listed below. This Board will serve a two-year term, from 2021 to 2023, at the conclusion of which the House of Delegates will elect a new Board.

 

If you wish to contact any member of the Board of Officers below please get in touch with:

 

IFAPP secretariat
p/a Business2gether
Leidsestraatweg 41-D
3443 BP WOERDEN
The Netherlands

E-mail: secretariat@ifapp.org

Phone: +31 6 2291 1039

 

Chamber of Commerce: 30224375

Marco-Romano-e1539672555526

President Marco Romano (Italy)

Until 31 October 2020 Dr Romano (MD, PhD, GFMD1) had, in his position of Executive Medical Director at Covance, full responsibility within the Medical Department including Clinical Development, Medical Support to Clinical Operations, Medical Monitoring and Medical Support to Pharmacovigilance Services. He left Covance and retired on 31 October 2020.

Dr Romano has over 30 years of pharmaceutical development experience, both in pharmaceutical companies and in clinical research organizations (CROs). He has successfully managed a number of Phase II, III and IV clinical trials, and, since 1998, has held senior management positions within the CRO sector such as Country Manager, Medical Director, and Chief Medical Officer.

Dr Romano obtained a diploma in Medicine at the University of Genoa (1983) followed by a post-graduate degree in Hygiene, Epidemiology and Public Health (1987), and another post-graduate degree in Clinical Pharmacology (1994). He is co-author of several scientific papers concerning mutagenesis and carcinogenesis, pharmacokinetics and pharmacodynamics of chemical compounds and glutathione metabolism.

Dr Romano has been a Member of the Italian Medical Association since 1983 and was President of the Italian Society of Pharmaceutical Medicine (SIMeF) from 2014 to 2020. He has been elected President of IFAPP for the period of 2020-2022.

 

1 GFMD: Global Fellow Medicines Development

Baroutsou Varvara

President-Elect Varvara (Barbara) Baroutsou (Greece)

Independent Consultant

Dr Baroutsou (MD, PhD, EMAUD1, GFMD2) is a licenced Physician certified in Internal Medicine. She studied in Greece, Sweden and France and worked as a Hospital Physician and Clinical Investigator in Greece and as a Pharmaceutical Physician in Clinical Development and Medical Affairs in Pharmaceutical Industry leadership roles in Greece, France and Switzerland with her latest position being Western Europe Chief Scientific Officer at Novartis. Dr Baroutsou has a wealth of experience in medicines development with a contribution to more than 200 global clinical development programmes that led to the successful introduction of innovative drugs and publications for the clinical practice of medicine.

Currently, Dr Baroutsou is an Independent Medical Consultant and Pharmaceutical Medicine Consultant, affiliated with the Greek Medical Schools’ postgraduate courses in Infectious Diseases, Molecular Basis of Human Diseases and Clinical Pharmacology Therapeutics. Simultaneously, Dr Baroutsou is the President of the Hellenic Society of Pharmaceutical Medicine, active with CME3 activities in collaboration with Biomedical Research Institutions and Medical Scientific Societies.

Moreover, Dr Baroutsou is a member of the EFGCP4 Core Faculty and an active Member of the IFAPP Ethics, External Affairs and Communication Working Groups. Her major inspiration lies in collaborating with academia, pharmaceutical medicine experts, clinical investigators, patient associations and regulators putting the patient at the centre of Research and Development and innovation in the healthcare agenda.

Dr Baroutsou is a purpose-driven leader, passionate about science, research and people. She is a strong believer of the expanded value proposition of Pharmaceutical Medicine as discipline bridging Research and Development with the practise of medicine and patient access to optimal care.

 

1 EMAUD: European Market Access University Diploma

2 GFMD: Global Fellow in Medicines Development

3 CME: Continuing Medical Education

4 EFGCP: European Forum for Good Clinical Practice

IFAPP-WORLD-2014-MARCH-page-3a-Kyko_Imamura-3

Past President Kyoko Imamura (Japan)

University of Tokyo

Dr Imamura graduated from Kumamoto University Medical School in 1982 and started resident training at Department of Orthopedic Surgery, Jikei University School of Medicine, Tokyo. She obtained a PhD in Medical Science (in Cellular Biology) from Jikei University School of Medicine in 1989, upon completion of study experience in clinical pharmacology at Dana Farber Cancer Institute, Harvard Medical School, USA. She also obtained a PhD (in Outcomes Research) from the London School of Hygiene and Tropical Medicine, University of London, UK, in 1995. She has a vast experience in medicines development and marketing in pharmaceutical companies (foreign-based) and Contract Research Organizations in Japan since 1995.

After a series of practices from basic science, clinical orthopedics and outcomes research, Dr Imamura built her career in the pharmaceutical industry by taking leading roles in Research and Development (R&D) and Medical Affairs. Since November 2018 she has been conducting research projects as the Project Professor of the Social Cooperation Program of IT Healthcare at the University of Tokyo.

Dr Imamura had three roles for her contribution to Pharmaceutical Medicine as a discipline and a profession as Chairperson of JAPhMed (Japanese Association of Pharmaceutical Medicine) until July 2015, and she has been active in promoting the medical perspectives and responsibilities in R&D and product life-cycle management. As a member of the Board of Directors for ACRP1, Japan, she promoted talent development of CRCs2 and CRAs3 involved in global clinical studies.

 

1 ACRP: Association of Clinical Research Professionals)

2 CRC: Clinical Research Coordinators

3 CRA: Clinical Research Associates

Brigitte Franke-Bray 2

Treasurer Brigitte Franke-Bray (Switzerland)

Independent Consultant

Dr Brigitte Franke-Bray FFPM1, GFMD2 was re-elected as Treasurer in June 2021. She is an independent consultant and a board-certified specialist in Pharmaceutical Medicine (FMH3/Switzerland). After her medical studies, she worked for several years in a German hospital (Internal Medicine, Pneumology, Allergology) before she joined the pharmaceutical industry (Ciba-Geigy/Sandoz, Basel, Switzerland), as international medical expert for respiratory diseases and then became the first Office Head/Medical Director for Quintiles in Switzerland.

In 2005 she joined the DIA (Drug Information Association) as the Director Europe, Middle East, Africa and later became their global Training Director for the development of scientific congresses and training courses in Pharmaceutical Medicine which she designed in collaboration with the major regulatory medicines agencies (EU, USA, Japan, China, Switzerland), the European Commission and ministries of health in the Middle East and Africa. Subsequently, Dr Franke-Bray became a clinical reviewer with Swissmedic, the Swiss Agency for Therapeutic products, before she worked for several years as a globally acting Medical Director in Novartis Basel, responsible for the development of medicines in respiratory diseases.

For 22 years Dr Franke-Bray was a board member of SGPM (Swiss Society of Pharmaceutical Medicine) and earlier of SwAPP (Swiss Association of Pharmaceutical Professionals) and she organised their joint annual symposium every year for over 20 years. Dr Franke-Bray is a member of the examination committee of the University of Basel, Switzerland for the board certification of physicians in Pharmaceutical Medicine as well as of various related Basel University diplomas and certificates, e.g. for ECPM, the European Course in Pharmaceutical Medicine.

Dr Franke-Bray collaborated in two of the EU Commission’s IMI (Innovative Medicine Initiative) projects, PharmaTrain (www.pharmatrain.eu) and EUPATI (www.eupati.eu,) where she deepened her knowledge of training course development in Pharmaceutical Medicine. Dr Franke-Bray is a member of the German and Swiss associations

1 FFPM: Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians United Kingdom

2 GFMD: Global Fellow Medicines Development

3 FMH: Foederatio Medicorum Helveticorum

Anna Jurczynska 2

Secretary Anna Jurczynska (Spain)

Independent consultant

Dr Jurczynska was elected Secretary of the Board of Officers in June 2021. She is an Independent Consultant and Co-founder of ANMAR Clinical Services and has an MBA1 from the University of Warsaw, Poland, and a PhD in Social Sciences with a specialisation in Health Care. She has a broad experience in the pharmaceutical industry (Upjohn Farmoquimica, Serono and IMTIX Sangstat) in Medical, Regulatory, Medical Science Liaison (MSL) and Marketing Departments.

Her main commitments were related to local and international clinical operations while in the Medical Department, with large responsibility for timely submission of Clinical Trials dossiers, correct performance and adequate outcomes and results of the trials. In the Regulatory Department, she was accountable for the supervision and development of new product registration dossiers for submission to Spanish Health Authorities and/or to the EMA2. Her position in the Medical Science Liaison and Marketing Departments was mainly related to contacts with Key Opinion Leaders and development of clinical protocols for post-authorisation studies.

Dr Jurczynska had a direct responsibility as General Manager of Business Administration at PAREXEL International, being its legal representative in Spain and overseeing all clinical and business operations in the country.

1MBA: Master of Business Administration

2 EMA: European Medicines Agency

Ghazaleh Gouya

Standing Officer Ghazaleh Gouya (Austria)

Gouya-Insights kg

Priv. Doz. Dr med Ghazaleh Gouya was elected Chair of the Communication Working Group. As founder of the Gouya-Insights KG, Dr Gouya takes leadership in clinical development for biotechnology, pharma and medical device companies to address clinical product development and regulatory compliance challenges. The cornerstone of this success is found in an expert team of scientists and medical experts in life science research. It is this insight that allows Gouya Insights to drive the clients from discovery through testing, clinical trials, regulatory approvals, and ultimately arrive at market in the most efficient manner.

Dr Gouya is board certified in Internal Medicine, Cardiology and Clinical Pharmacology, with more than 20 years of clinical and research experience. After clinical practice in internal medicine and cardiology in UK and Austria, she joined the cardiovascular research team at the Department of Clinical Pharmacology, Medical University Vienna, Austria. During her stay at the Medical University Vienna, she finalized her training in cardiology focused on heart failure disease management.

While working at the Department of Clinical Pharmacology Dr Gouya gained fundamental clinical research experience (investigator driven and industry sponsored cardiovascular and metabolic studies). She participated in clinical trials as sub- and principal investigator where she was responsible for developing concept, design, protocol, performance, and management strategies for clinical phase I-III trials in the cardiovascular and metabolic area. Dr Gouya published more than 30 research papers in peer reviewed journals and 3 book-chapters and actively participated in national and international congresses. In March 2015 she was awarded the title Associate Professor for Internal Medicine from the Medical University Vienna with her habilitation thesis "Efficacy and Effectiveness of Antithrombotic Therapy".

In 2008 Dr Gouya successfully applied, together with a large group of representatives of FP7 clinical infrastructures and EFPIA members, for a European funded project (Innovative Medicines Initiative, IMI) of education and training in medicines development (www.emtrain.eu). She was scientific head and head of communication of EMTRAIN until 2012. After her academic career, she joined a global CRO as medical director. Dr Gouya has been involved in a number of product development processes where she substantially added to the strategy for the project and protocol development in identifying the best approach for the right patient at the right site up to the completion of documentation for market approval. Dr Gouya is a member of the Austrian association GPMed.

Kotone Matsuyama

Standing Officer Kotone Matsuyama (Japan)

Nippon medical school

Professor Kotone Matsuyama GFMD1 was elected Chair of the Ethics Working Group in June 2021. From June 2019 to June 2021 she was Secretary of the Board of Officers. She is currently Professor, Department of Health Policy and Management, and Vice President of Center for Strategic Research Initiative, Nippon Medical School.

Professor Matsuyma graduated from Kyoto University Faculty of Pharmaceutical Science and obtained a license as Pharmacist. She started her Research and Development (R&D) career as a data manager in 2003 and she has worked as a project manager since 2005. She spent 12 years at the Translational Research Informatics Center, Foundation for Biomedical Research and Innovation, Kobe, and 2.5 years as a Lecturer at the Center for Quality Assurance in R&D, Kyoto Prefectural University of Medicine.

Professor Matsuyama has been a member of the Board of Directors of the Japanese Association of Pharmaceutical Medicine (JAPhMed) since October 2018. She is also a Project Coordinator, Clinical Development, Program for Drug Discovery and Medical Technology Platforms, RIKEN Research Cluster for Innovation, an adjunct Lecturer, Clinical Pharmacology, Faculty of Medicine, Oita University, and an adjunct Lecturer of Bioethics, Faculty of Medicine, Kyoto Prefectural University of Medicine.

Professor Matsuyama has managed or supported many R&D projects initiated from academia, not only for drugs but also medical devices and regenerative medicines. Her specialty is process optimisation throughout a project, recently known as a clinical planning method using Quality by Design. She won awards of excellence at the 36th annual congress of the Japanese Society of Clinical Pharmacology and Therapeutics and the 7th annual congress of the Japan Society of Clinical Trials and Research.

Her secondary research area is research ethics, and she lectures many educational ethics programs in academia. Professor Matsuyama started her research programme in ethics with Professor Kouichi Setoyama, Kyoto Prefectural University of Medicine, especially on the evaluation methodology to visualise ethical decision-making in medical research. She collaborates with the Japanese AMED grant project named “Development of a Model Evaluation Program of the Effects of Research Ethics Education with an Interdisciplinary Approach.” Professor Matsuyama is a member of the Japanese association JAPhMed.


1
GFMD: Global Fellow Medicines Development

Birka Lehmann

Standing Officer Birka Lehmann(Germany)

University of Bonn

Dr Birka Lehmann was elected Chair of the Certification and Education Working Group in June 2021. She has been Senior Expert for Drug Regulatory Affairs and Lecturer at the University of Bonn, Germany, since 1998.

Dr Birka Lehmann studied Medicines at the Free University Berlin and trained at the paediatric clinic (Kinderklinik) Norderney in Germany. Her working experience includes 9 years preclinical assessment in the division ‘Pharmacology and Toxicology’ of the German Medicines Regulatory Agency (BfArM1) and she served as Head of Unit ‘Decentralised Procedure’ (1996 - 2002) and as Deputy Head of the EU Division (2000 - 2002). She was a member of and chaired the Mutual Recognition Facilitation Group and served as expert to the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA). From 2002 – 2006 she joined the Directorate-General Enterprise and Industry of the European Commission as expert on secondment to the unit ‘Pharmaceuticals’ responsible for inter alia Marketing Authorisation and implementation of the Clinical Trials Directive.

From September 2006 to October 2011 Dr Lehmann was Head of Division 3 Marketing Authorisation procedure at the BfArM comprising several indication areas including cardiovascular and pulmonary diseases, antibiotics and dermatology. Dr Lehmann was then Head of the Executive Department EU and International Affairs of the BfArM from October 2011 till the end of 2015 and she was a member of the Paediatric Committee at the European Medicines Agency from 2007 to 2016. Dr Lehmann is a member of the German association DGPharMed.

1BfArM: Bundesamt für Arzneimittel und Medizinprodukte (Federal Institute for Drugs and Medical Devices)

Cordula Landgraf

Standing Officer Cordula Landgraf (Switzerland)

SCTO

Cordula Landgraf was elected Chair of the External Affairs Working Group in June 2021. She is a licensed pharmacist with more than 20 years of knowledge and experience in Regulatory Affairs as well as Regulatory Intelligence/Policy work.

After her studies of pharmacy at Johann Wolfgang von Goethe University, Frankfurt, Germany, she started her professional life in a public pharmacy in Germany before joining the pharmaceutical industry (ICN, Altana Pharma) for several years. In her position as Regulatory Intelligence Manager she gathered experience in monitoring and assessing the international regulatory environment including authority decisions and competitor information, she actively contributed to developmental Regulatory Affairs work from early development on and participated in strategic regulatory decision-making.

In 2007, Cordula Landgraf joined Swissmedic, the Swiss Agency for Therapeutic products, as Head of Networking. In this function she substantially contributed to building up Swissmedic’s national and international cooperation and developed the agency’s policy on stakeholder engagement and international cooperation. She represented Swissmedic in various international committees and fora, e.g. as a Member of the ICH (International Council on Harmonisation) Management Committee and Assembly. During this time, she also started lecturing at various universities, e.g. ETH Zurich[1] (Switzerland), University of Bonn[2] (Germany) and was a speaker at international conferences.

Subsequently, Cordula Landgraf was Head of Public Affairs & Regulatory Policy at SFL, a Services for Life Sciences consultancy (Basel, Switzerland) where she had the oversight of client projects in the areas of public affairs, association management and regulatory intelligence.

Since June 2020, Cordula Landgraf is Director Communications & Stakeholder Engagement at the Swiss Clinical Trial Organisation (SCTO) in Bern, Switzerland. Working closely with management and the Steering Board, she is responsible to further develop the SCTO’s communication strategy and seeking ways to enhance strategic collaboration with stakeholders – with a special emphasis on patient & public involvement (PPI) in academic clinical research. Cordula Landgraf has just been elected to represent the SCTO in the Executive Board of EUPATI Switzerland[3]. Cordula Landgraf is a member of the Swiss Association SwAPP.

[1] https://chab.ethz.ch/en/studies/master/pharmsciences.html

[1] https://www.dgra.de/deutsch/studiengang/

[1] https://ch.eupati.eu/

 

 

Annette Mollet

Standing Officer Annette Mollet (Switzerland)

ECPM/University of Basel

Dr Annette Mollet, PhD, dipl. Pharm. Med. SwAPP, MBA was elected Chair of the Young Professionals Working Group in June 2021. She has been Managing Director and Head of Education & Training of the European Center of Pharmaceutical Medicine at the University of Basel, Switzerland since 1997.

She received her Master in Pharmacy from the University of Basel, her PhD in Neurobiology from the Swiss Federal Institute of Technology in Zurich and her MBA in International Health from the Swiss Tropical and Public Health Institute (Swiss TPH) in Basel.

Dr Mollet joined the pharmaceutical industry in 1994 where she worked in the clinical Research & Development department at F. Hoffmann-La Roche Ltd. in Basel and later as a Medical and Product Manager responsible for oncology products at the Swiss affiliate of Roche.

She has been chairing the Federal Expert Committee for the Evaluation of Radioactive Drugs, a joint committee of the Swiss Agency for Therapeutic Products (Swissmedic) and the Swiss Federal Office of Public Health (BAG) since 2007, being a member since 1994. She was a founding member and Member of the Board of the Swiss Association of Pharmaceutical Professionals (SwAPP), being responsible for its commission for specialty training and Continuing Professional Education (CPD) until 2018.

From 2009-2014 she was involved in the PharmaTrain project, an Innovative Medicines Initiative (IMI) for training in Pharmaceutical Medicine, and she chairs the PharmaTrain Federation working group of course providers in Pharmaceutical Medicine.

In 2016 Dr Mollet was elected Board Member of the Association of Graduate Regulatory Educators (AGRE global) based in the USA. She is the co-author of the Dictionary of Pharmaceutical Medicine by Springer (fourth edition, 2017) and was a member of the working party on the “PharmaTrain Syllabus for Pharmaceutical Medicine” led by the Royal College of Physicians in London. Since April 2017 she has been part of the Committee of Continuing Education of the University of Basel. In July 2018 she was elected as an External Examiner to the Trinity College of the University of Dublin, Ireland, for the curriculum in Pharmaceutical Medicine.